Ophthalmology Center of Excellence
Orsini’s Ophthalmology Center of Excellence launched in 2020 with our first program for progressive keratoconus. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.
Benefits
Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.
Experience compassionate care that prioritizes patients and their families. Our team supports patients of all ages, from infants to the elderly, extending care to the entire care team.
Secure treatment coverage with assistance navigating payor and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.
Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.
Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.
Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.
Support
Explore the ophthalmology conditions and therapies Orsini supports below.
Corneal ectasia is a condition characterized by progressive thinning and bulging of the cornea, the transparent front part of the eye. Commonly associated with conditions like keratoconus, post-LASIK surgery complications, or corneal degeneration, corneal ectasia results in an altered corneal shape, impacting vision. Symptoms include blurred or distorted vision, sensitivity to light, and difficulty with night vision.
| Full Name | Photrexa® (riboflavin 5’-phosphate ophthalmic solution) |
| Drug | Photrexa |
| Manufacturer | Glaukos |
| Route of Administration | Intraocular |
| Site of Care | Healthcare Facility |
| Approved Indication | The treatment of progressive keratoconus (1.1) and corneal ectasia following refractive surgery |
| Disease | Progressive Keratoconus; Corneal Ectasia |
| Therapeutic Area | Ophthalmology |
| Enrollment Form Link | Photrexa Enrollment Form |
| Phone Number | 800-550-7207 |
| Fax Number | 877-277-3139 |
Idiopathic macular telangiectasia (MacTel) type 2 is a rare, progressive eye disease that affects the part of the retina responsible for central vision. It typically occurs in both eyes and leads to gradual vision loss, often beginning with subtle symptoms like blurred or distorted vision. While the exact cause is unknown, genetic factors and systemic conditions like diabetes may contribute to its development.
| Full Name | ENCELTO™ (revakinagene taroretcel-lwey) |
| Drug | Encelto |
| Manufacturer | Neurotech Pharmaceuticals, Inc. |
| Route of Administration | Intravitreal |
| Site of Care | Healthcare facility |
| Approved Indication | Indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel) |
| Disease | Idiopathic macular telangiectasia type 2 (MacTel) |
| Therapeutic Area | Ophthalmology; Cell & Gene Therapy |
| Enrollment Form Link | Start Form |
| Phone Number | 888-477-1165 |
| Product Website | ENCELTO.com/ecp |
Ocular hypertension is a condition where the pressure inside the eye, called intraocular pressure, is higher than normal without any detectable damage to the optic nerve or loss of vision. It occurs when the eye’s fluid doesn’t drain properly, leading to pressure buildup. Ocular hypertension increases the risk of developing glaucoma and is often discovered during routine eye checks.
| Full Name | iDose® TR (travoprost intracameral implant) |
| Drug | travoprost |
| Manufacturer | Glaukos Corporation |
| Route of Administration | Intracameral |
| Site of Care | Healthcare facility |
| Approved Indication | Indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension |
| Disease | Open-angle glaucoma; Ocular hypertension |
| Therapeutic Area | Ophthalmology |
| Enrollment Form Link | Start Form |
| Phone Number | 800-550-7202 |
| Fax Number | 877-277-3139 |
| Product Website | idosetrhcp.com |
Open-angle glaucoma is a form of glaucoma, a chronic eye disease that gradually damages the optic nerve, often leading to irreversible vision loss. It occurs when the eye’s drainage system becomes inefficient at draining fluid. This causes increased intraocular pressure, which slowly harms the optic nerve over time. The condition typically develops without noticeable symptoms, making regular eye exams crucial for early detection.
| Full Name | iDose® TR (travoprost intracameral implant) |
| Drug | travoprost |
| Manufacturer | Glaukos Corporation |
| Route of Administration | Intracameral |
| Site of Care | Healthcare facility |
| Approved Indication | Indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension |
| Disease | Open-angle glaucoma; Ocular hypertension |
| Therapeutic Area | Ophthalmology |
| Enrollment Form Link | Start Form |
| Phone Number | 800-550-7202 |
| Fax Number | 877-277-3139 |
| Product Website | idosetrhcp.com |
Progressive keratoconus is a degenerative eye condition in which the cornea gradually thins and bulges into a cone-like shape. This distortion leads to increasing levels of irregular astigmatism and nearsightedness, causing blurred and distorted vision. The disease typically begins in adolescence or early adulthood and can progress into the mid-30s, often affecting both eyes to varying degrees.
| Full Name | Photrexa® (riboflavin 5’-phosphate ophthalmic solution) |
| Drug | Photrexa |
| Manufacturer | Glaukos |
| Route of Administration | Intraocular |
| Site of Care | Healthcare Facility |
| Approved Indication | The treatment of progressive keratoconus (1.1) and corneal ectasia following refractive surgery |
| Disease | Progressive Keratoconus; Corneal Ectasia |
| Therapeutic Area | Ophthalmology |
| Enrollment Form Link | Photrexa Enrollment Form |
| Phone Number | 800-550-7207 |
| Fax Number | 877-277-3139 |
The Alex Rezcalla Foundation advances the development of therapies for individuals with Duchenne muscular dystrophy (DMD) through advocacy and research funding. It raises awareness of the DMD experience by hosting events, engaging the public, and building networks of support.
Learn more at alexrezkallafoundation.org
The Amyloidosis Research improves the lives of patients with amyloidosis and accelerates cutting edge research through collaborative, groundbreaking initiatives. ARC provides support, information, and resources to patients and caregivers, empowering them to access the best care possible.
Learn more at aci.org
Cure SMA is dedicated to finding treatments and a cure for spinal muscular atrophy (SMA) by funding research and supporting families. Since 1984, Cure SMA has grown to be the largest U.S.-based network of individuals, families, clinicians, and research scientists working together to advance SMA research, support individuals and families impacted by SMA, and educate public and professional communities about SMA.
Learn more at www.curesma.org
The US Hereditary Angioedema Association (HAEA) is a 501 (c)(3) non-profit advocacy and research organization serving people living with the rare genetic condition, Hereditary Angioedema (HAE), and their families. Founded and staffed by people with HAE and caregivers, the US HAEA is committed to actively engaging our community in a wide variety of grassroots activities that promote HAE education and awareness.
Learn more at haea.org
The HypoPARAthyroidism Association is a non-profit patient association working to improve the lives of people impacted by hypoPARAthyroidism through education, support, research, and advocacy. They raise awareness of hypoPARAthyroidism and bring change to the lives of those affected.
Learn more at hypopara.org
Jett Foundation empowers people and families impacted by Duchenne muscular dystrophy through the development of transformative programming, educational opportunities, and ongoing support for every stage of a Duchenne journey.
Learn more at jettfoundation.org
Muscular Dystrophy Association (MDA) is the #1 voluntary health organization in the United States for people living with muscular dystrophy, ALS, and over 300 other neuromuscular conditions. For 75 years, MDA has led the way in accelerating research, advancing care, and advocating support and inclusion of families living with neuromuscular disease.
Learn more at mda.org
The National MPS Society is committed to making a difference in the lives of MPS families through support, research, education, and advocacy. Families from around the world gain a better understanding of these rare genetically determined diseases through the Society’s assistance in linking them with healthcare professionals, researchers, and, perhaps most importantly, each other.
Learn more at mpssociety.org
The National Niemann-Pick Disease Foundation, Inc. (NNPDF) is a non-profit, patient advocacy and family support organization dedicated to supporting and empowering patients and families affected by Niemann-Pick disease, through education, collaboration and research. Founded in 1993, NNPDF serves families throughout the nation at all stages of their Niemann-Pick journey.
Learn more at nnpdf.org
The National PKU Alliance (NPKUA) works to improves the lives of individuals with PKU, pursue a cure by expanding research, and provide education and support to individuals living with PKU and their caregivers. Since its inception in 2008, NPKUA has supported numerous successful fundraising events, conferences, and internal support programs and has remained steadfast in its support of research endeavors.
Learn more at npkua.org
Parent Project Muscular Dystrophy (PPMD) is the largest nonprofit organization in the United States focused entirely on Duchenne muscular dystrophy. They take a comprehensive approach in the fight against Duchenne—funding research, raising awareness, promoting advocacy, connecting the community, and broadening treatment options.
Learn more at parentprojectmd.org
The Pompe Alliance is a Public Services Organization dedicated to the ideas of support, empowerment, and progress. It seeks to provide supportive services and information to patients, caregivers, medical professionals, and community stakeholders through a number of initiatives: financial assistance, advocacy, education, mentoring, and research recruitment
Learn more at pompealliance.com
The mission of the Pulmonary Fibrosis Foundation is to accelerate the development of new treatments and ultimately a cure for pulmonary fibrosis. Until this goal is achieved, the PFF is committed to advancing improved care of patients with PF and providing unequaled support and education resources for patients, caregivers, family members, and health care providers.
Learn more at pulmonaryfibrosis.org
The United Pompe Foundation was formed to assist patients and/or their families with medical costs and other expenses that these patents and families face and may not be able to cover, or fully cover, through their insurance.
Learn more at unitedpompe.com